Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it will receive CNY 20 million in an equity round of funding on November 8, 2023. The transaction will include participation from returning investor, from returning investor Vcanbio Cell & Gene Engineering Corp., Ltd. The transaction has been approved at the fifth extraordinary meeting of Vcanbio Cell & Gene Engineering Corp., Ltd's eleventh session of the board of directors.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.18 CNY | -7.73% | +13.37% | -0.44% |
1st Jan change | Capi. | |
---|---|---|
-0.44% | 1.29B | |
-1.29% | 12.64B | |
-0.47% | 8.46B | |
+22.61% | 5.27B | |
-2.03% | 4.49B | |
-53.56% | 3.11B | |
+19.30% | 2.87B | |
+33.07% | 2.31B | |
-8.42% | 2.23B | |
-3.55% | 1.89B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd